Elutia Inc. (ELUT)vsMerck & Company Inc (MRK)
ELUT
Elutia Inc.
$1.00
0.00%
HEALTHCARE · Cap: $49.82M
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 528746% more annual revenue ($65.01B vs $12.29M). ELUT leads profitability with a 434.2% profit margin vs 28.1%. MRK earns a higher WallStSmart Score of 59/100 (C).
ELUT
Hold41
out of 100
Grade: D
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+31.3%
Fair Value
$1.31
Current Price
$1.00
$0.31 discount
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 434 of every $100 in revenue as profit
Reasonable price relative to book value
16.2% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Negative free cash flow — burning cash
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : ELUT
The strongest argument for ELUT centers on Profit Margin, Price/Book, Revenue Growth. Profitability is solid with margins at 434.2% and operating margin at -167.9%. Revenue growth of 16.2% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : ELUT
The primary concerns for ELUT are EPS Growth, Market Cap, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ELUT profiles as a growth stock while MRK is a value play — different risk/reward profiles.
ELUT carries more volatility with a beta of 0.71 — expect wider price swings.
ELUT is growing revenue faster at 16.2% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 41/100), backed by strong 28.1% margins. ELUT offers better value entry with a 31.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elutia Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?